• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Dong wu xue yan jiu = Zoological Research >King cobra peptide OH-CATH30 as a potential candidate drug through clinic drug-resistant isolates
【2h】

King cobra peptide OH-CATH30 as a potential candidate drug through clinic drug-resistant isolates

机译：眼镜王蛇肽OH-CATH30通过临床耐药菌株成为潜在的候选药物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cationic antimicrobial peptides (AMPs) are considered as important candidate therapeutic agents, which exert potent microbicidal properties against bacteria, fungi and some viruses. Based on our previous findings king cobra cathelicidin (OH-CATH) is a 34-amino acid peptide that exerts strong antibacterial and weak hemolytic activity. The aim of this research is to evaluate the efficacy of both OH-CATH30 and its analog D-OH-CATH30 against clinical isolates comparing with routinely utilized antibiotics in vitro. In this study, 584 clinical isolates were tested (spanning 2013–2016) and the efficacy of the candidate peptides and antibiotics were determined by a broth microdilution method according to the CLSI guidelines. Among the 584 clinical isolates, 85% were susceptible to OH-CATH30 and its analogs. Both L- and D-OH-CATH30 showed higher efficacy against (toward) Gram-positive bacteria and stronger antibacterial activity against nearly all Gram-negative bacteria tested compare with antibiotics. The highest bactericidal activity was detected against Acinetobacter spp., including multi-drug-resistant Acinetobacter baumannii (MRAB) and methicillin-resistant Staphylococcus aureus (MRSA). The overall efficacy of OH-CATH30 and its analogs was higher than that of the 9 routinely used antibiotics. OH-CATH30 is a promising candidate drug for the treatment of a wide variety of bacterial infections which are resistant to many routinely used antimicrobial agents.
机译：阳离子抗菌肽（AMPs）被认为是重要的候选治疗剂，可对细菌，真菌和某些病毒发挥有效的杀菌作用。根据我们先前的发现，眼镜王蛇抗胆碱（OH-CATH）是一种34个氨基酸的肽，具有强抗菌和弱溶血活性。这项研究的目的是评估OH-CATH30及其类似物D-OH-CATH30对临床分离株与常规体外使用的抗生素的疗效。在这项研究中，测试了584种临床分离株（2013年至2016年），并根据CLSI指南通过肉汤微量稀释法确定了候选肽和抗生素的功效。在584株临床分离株中，85％对OH-CATH30及其类似物敏感。与抗生素相比，L-和D-OH-CATH30对革兰氏阳性细菌（朝革兰氏阳性细菌）均显示出更高的功效，并且对几乎所有测试的革兰氏阴性细菌均具有更强的抗菌活性。检测到对不动杆菌属具有最高的杀菌活性，包括多重耐药性鲍曼不动杆菌（MRAB）和耐甲氧西林金黄色葡萄球菌（MRSA）。 OH-CATH30及其类似物的总体疗效高于常规使用的9种抗生素。 OH-CATH30是一种有前途的候选药物，可用于治疗对许多常规使用的抗菌剂具有耐药性的多种细菌感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号